Developments in the treatment of juvenile arthritis

Bibliography

• OEN KG: Comparative epidemiology of the rheumatic diseases in children. Curc Opin. Rheumatol (2000) 12(5):410–414.
   PubMedGoogle Scholar
• GARE BA: Juvenile arthritis- who gets it, where and when? A review of the current data on incidence and prevalence. Clin. Exp. Rheumatol (1999) 17(3):367–374.
   PubMed Web of Science ®Google Scholar
• MANNERS PJ, BOWER C: Worldwide prevalence of juvenile arthritis why does it vary so much?' Rheumatol (2002) 29:1520–1530.
   Google Scholar
• LAWRENCE RC, HELMICK CG, ARNETT FC et al.: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritic Rheum. (1998) 41(5)778–799.
   Google Scholar
• CASSIDY JT, PETTY RE: Juvenile rheumatoid arthritis. In: Textbook of pediatric rheumatology WB Saunders, Philadelphia, USA (1995):133–223.
   Google Scholar
• JACOBS JC: Juvenile rheumatoid arthritis. In: Pediatric rheumatology for the practitioner. Springer-Verlag, New York, NY, USA (1993):231–359.
   Google Scholar
• SIEGEL DM, BAUM J: Juvenile arthritis. Prim. Care (1993) 20:883–893.
   PubMed Web of Science ®Google Scholar
• SULLIVAN DB, CASSIDY JT, PETTY RE: Pathogenic implications of age of onset in juvenile rheumatoid arthritis. Arthritic Rheum. (1975) 18:251–255.
   PubMedGoogle Scholar
• CASSIDY JT, LEVINSON JE, BASS JC et al.: A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritic Rheum. (1986) 29:274–281.
   PubMed Web of Science ®Google Scholar
• PETTY RE, SOUTHWOOD TR, BAUM J et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. j. Rheumatol (1998) 25(10):1991–1994.
   PubMedGoogle Scholar
• •This paper summarises the new classification criteria.
   Google Scholar
• DENARDO BA, MILLER LC, SCHALLER JG et al: Young children with juvenile rheumatoid arthritis (JA) are developmentally delayed in gross and fine motor skills. Arthritic Rheum. (1996) 39\(Suppl. 9):51715.
   Google Scholar
• DAVID J, COOPER C, HICKEY L et al:The functional and psychological outcomes of juvenile chronic arthritis in young adulthood. Br. Rheumatol (1994) 33:876–881.
   PubMedGoogle Scholar
• WOO P, WEDDERBURN LR: Juvenile chronic arthritis. Lancet (1998) 351:969–973.
   PubMed Web of Science ®Google Scholar
• FANTINI F, GERLONI V, GATTINARA M et al.: Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10-year follow up [abstract]. Arthritis Rheum. (1999) 42(9 Suppl.):S168.
   Google Scholar
• BIANCHI ML, BARDARE M, GALBIATI E et al.: Bone development in juvenile rheumatoid arthritis. In: Paediatric osteology Prevention of osteoporosis - a paediatric task?Schönau E, Matkovic V, (Eds). Proceedings of the 2'd International Workshop on Paediatric Osteology Elsevier Science, Cologne, Singapore (1998):173–181.
   Google Scholar
• BERNSTEIN B, TAKAHASHI M, HANSON V: Cardiac involvement in juvenile rheumatoid arthritis. Pediati: (1974) 85(3):313–317.
   PubMedGoogle Scholar
• WALLACE CA, LEVINSON JE: Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum. Dis. Clin. North Am. (1991) 17(4):891–905.
   PubMed Web of Science ®Google Scholar
• GARE BA, FASTH A: The natural history of juvenile chronic arthritis: a population based cohort study, I: Onset and disease process. Rheumatol (1995) 22:295–307.
   Google Scholar
• GUILLAUME S, PRIEUR AM, COSTE J et al.: Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis. Arthritis Rheum. (2000) 43:1858–1865.
   PubMedGoogle Scholar
• MINDEN K, KIESSLING U, LISTING Jet al.: Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. Rheumatol (2000) 27:2256–2263.
   Google Scholar
• PETERSON LS, MASON T, NELSON AM et al.: Psychosocial outcomes and health status of adults who have had juvenile rheumatoid arthritis: a controlled, population-based study. Arthritis Rheum. (1997) 40:2235–2240.
   PubMedGoogle Scholar
• ZAK M, PEDERSEN FK: Juvenile chronicarthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford) (2000) 39:198–204.
   PubMed Web of Science ®Google Scholar
• FOSTER HE, MARSHALL N, MYERS A et al.: Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. (2003) 48(3):767–775.
   PubMed Web of Science ®Google Scholar
• PACKHAM JC, HALL MA, PIMM TJ: Long-term follow-up of 246 adults with juvenile idiopathic arthritis: predictive factors for mood and pain. Rheumatology (2002) 41(12):1444–1449.
   PubMed Web of Science ®Google Scholar
• ••These Packham papers are essentially onereport published separately as individual papers looking into various aspects of long-term outcome in children with JA.
   Google Scholar
• PACKHAM JC, HALL MA: Long-term follow-up of 246 adults with juvenile idiopathic arthritis: social function, relationships and sexual activity. Rheumatology (2002) 41(12):1440–1443.
   PubMed Web of Science ®Google Scholar
• PACKHAM JC, HALL MA: Long-term follow-up of 246 adults with juvenile idiopathic arthritis: education and employment. Rheumatology (2002) 41(12):1436–1439.
   PubMed Web of Science ®Google Scholar
• PACKHAM JC, HALL MA: Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (2002) 41(12):1428–1435.
   PubMed Web of Science ®Google Scholar
• EGSMOSE C, LUND B, BORG G et al: Patients with rheumatoid arthritis benefit from early 2nd line therapy:5-year follow-up of a prospective double blind placebo controlled study. J. Rheumatol (1995) 22:2208–2213.
   PubMed Web of Science ®Google Scholar
• VAN DER HEIDE A, JACOBS JWG, BIJLSMA JWJ et al.: The effectiveness of early treatment with 'second-line' antirheumatic drugs: a randomized, controlled trial. Ann. Intern. Med. (1996) 124:699–707.
   Google Scholar
• FLATO B, AASLAND A, VINJE 0, FORRE 0: Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. Rheumatol (1998) 25:366–375.
   Google Scholar
• ••An important paper demonstrating therationale for early, aggressive intervention in JA.
   Google Scholar
• FANTINI F, GERLONI V, GATTINARA M et al.: Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10-year follow up [abstract]. Arthritis Rheum. (1999) 42(9 Suppl.):S168.
   Google Scholar
• ••An important paper demonstrating therationale for early, aggressive intervention in JA.
   Google Scholar
• GIANNINI EH, CASSIDY JT, BREWER EJ et al.: Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin. Arthritis Rheum. (1993) 23:34–46.
   PubMedGoogle Scholar
• ••An important paper examining the efficacyof traditional DMARDs of RA treatment with experience in JA.
   Google Scholar
• CLEARY AG, MURPHY HD, DAVIDSON JE: Intra-articular corticosteroid injections in juvenile idiopathic arthritis (review). Arch. Dis. Child. (2003) 88(3):192–196.
   PubMedGoogle Scholar
• ATHREYA BH, CASSIDY JT: Current status of the medical treatment of children with juvenile rheumatoid arthritis. Rheum. Dis. Clin. North Am. (1991) 17:871–889.
   PubMed Web of Science ®Google Scholar
• SINGSEN BH, GOLDBACH-MANSKY R: Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders. Rheum. Dis. Clin. North Am. (1997) 23:811–840.
   PubMedGoogle Scholar
• GIANNINI EH, BREWER EJ, KUZMINA N et al.: Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR. double-blind, placebo-controlled trial. N Engl. I Med. (1992) 326:1043–1049.
   PubMedGoogle Scholar
• •The first and only randomised, controlled methotrexate trial in children with JA.
   Google Scholar
• HALLE F, PRIEUR AM: Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin. Exp. Rheumatol (1991) 9:297–302.
   PubMedGoogle Scholar
• GOTTLIEB BS, KEENAN GE LU T, ILOWITE NT: Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics (1997) 100(6)994–997.
   Google Scholar
• WALLACE CA, SHERRY DD: Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. Rheumatol (1992) 19:1604–1607.
   Web of Science ®Google Scholar
• REIFF A, SHAHAM B, WOOD BP et al.:High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin. Exp. Rheumatol (1995) 13:113–118.
   PubMed Web of Science ®Google Scholar
• HAREL L, WAGNER-WEINER L, POZNANSKI AK et al.: Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum. (1993) 36:1370–1374.
   PubMed Web of Science ®Google Scholar
• RAVELLI A, GERLONI V, CORONA F et al.: Oral versus intramuscular methotrexate in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. Clin. Exp. Rheumatol (1998) 16:181–183.
   PubMedGoogle Scholar
• VAN ROSSUM MAJ, FISELIER TJW, FRANSSEN MJAM et al.: Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum. (1998) 41:808–816.
   PubMedGoogle Scholar
• ••The first and only randomised, controlledsulfasalazine trial in children with JA.
   Google Scholar
• HUANG JL, CHEN LC: Sulphasalazine in the treatment of children with chronic arthritis. Clin. Rheumatol (1998) 17:359–363.
   PubMedGoogle Scholar
• SAVOLAINEN HA, KAUTIAINEN H, ISOMAKI H et al.: Azathioprine in patients with juvenile chronic arthritis: a long-term follow-up study. J. Rheumatol (1997) 24:2444–2450.
   PubMedGoogle Scholar
• ANDRASCH RH, PIROFSKY B, BURNS RP: Immunosuppressive therapy for severe chronic uveitis. Arch. Ophthalmol (1978) 96:247–251.
   PubMed Web of Science ®Google Scholar
• REIFF A, RAWLINGS DJ, SHAHAM B et al.: Preliminary evidence for cyclosporine A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. Rheumatol (1997) 24:2436–2443.
   Web of Science ®Google Scholar
• FANTINI F: Cyclosporine therapy in systemic juvenile rheumatoid arthritis (Still's disease): an open pilot prospective study. In: Cyclosporine in Autoimmune Diseases. Bonomo L (Ed). Ii Pensiero Scientifico Editore, Rome, Italy (1990):133–142.
   Google Scholar
• GERLONI V, CIMAZ R, GATTINARA M et al.: Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford) (2001) 40:907–913.
   Google Scholar
• D'AMATO RJ, LOUGHAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91:4082–4085.
   PubMed Web of Science ®Google Scholar
• ZWINGENBERGER K, VVENDT S: Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations. Inflamm. (1996) 46:177–211.
   Google Scholar
• CORRAL LG, HASLETT PA, MULLER GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. Immunol (1999) 163:380–386.
   Web of Science ®Google Scholar
• BESSMERTNY 0, Pham T: Thalidomide use in pediatric patients. Ann. Pharmacother: (2002) 36(3):521–525.
   PubMedGoogle Scholar
• KARIM MY, RUIZ-IRASTORZA G, KHAMASHTA MA et al.: Update on therapy-thalidomide in the treatment of lupus. Lupus (2001) 10(3):188–192.
   PubMed Web of Science ®Google Scholar
• SCHECHTER SJ, SUNDEL R, OLIVEIRA K et al.: Thalidomide for severe systemic onset JIA. Arthritis Rheum. (2003) 48\(Suppl. 9):S122.
   Google Scholar
• WALLACE CA, SHERRY DD: Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritic Rheum. (1997) 40:1852–1855.
   PubMedGoogle Scholar
• EMERY P, ZEIDLER H, KVIEN TK et al.: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet (1999) 354:2106–2111.
   PubMed Web of Science ®Google Scholar
• SIMON LS, WEAVER AL, GRAHAM DY et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 282:1921–1928.
   PubMed Web of Science ®Google Scholar
• BENSEN WG, FIECHTNER JJ, MCMILLEN JI et al.: Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin. Proc. (1999) 74:1095–105.
   PubMed Web of Science ®Google Scholar
• DAY R, MORRISON B, LUZA A, CASTANEDA 0 et al.: A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib versus ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch. Intern. Med. (2000) 160:1781–1787.
   Google Scholar
• EHRICH EW, DALLOB A, DE LEPELEIRE I et al.: Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin. Pharmacol Ther. (1999) 65:336–347.
   Google Scholar
• BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl. I Med. (2000) 343(21):1520–1528.
   PubMed Web of Science ®Google Scholar
• KISS MH, REIFF A, REICIN AS et al.: Rofecoxib Demonstrates efficacy and tolerability in children and adolescents (ages 2–17 years) with juvenile rheumatoid arthritis (JRA). In a 12-week randomized study. Arthritic Rheum. (2003) 48\(Suppl. 9):51698.
   Google Scholar
• •The first abstract on experience with COX-2 inhibitors in JA.
   Google Scholar
• SMOLEN JS, KALDEN JR, SCOTT DL et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double blind, randomized, multicenter trial. Lancet (1999) 353:259–266.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, FLEISCHMANN RM, STRAND V, for the Leflunomide RA Investigators Group: Efficacy of leflunomide versus placebo versus methotrexate in early and late rheumatoid arthritis. Arthritis Rheum. (1998) 41(9 Suppl.):S155.
   Google Scholar
• SILVERMAN E, SPIEGEL L, JUNG LK et al.: Efficacy and Safety of Leflunomide (LEF) versus Methotrexate (MTX) in the Treatment of Pediatric Patients with Juvenile Rheumatoid Arthritis (JRA) Arthritic Rheum. (2003) 43:(Suppl. 9) (LB Abstract).
   Google Scholar
• EMERY P, BREEDVELD FC, LEMMEL EM et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2000) 39(6):655–665.
   PubMed Web of Science ®Google Scholar
• GOEL A, LONDINO AV JR: FK506 in severe treatment resistant juvenile rheumatoid arthritis (JA). Arthritic Rheum. (1996) 39\(Suppl. 9):5192.
   Google Scholar
• COHN RG, MIRKOVICH A, DUNLAP B et al.: Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation (1999) 68:411–418.
   PubMed Web of Science ®Google Scholar
• GOLDBLUM R: Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin. Exp. Rheumatol (1993) 11(8 Suppl.):S117–S119.
   Google Scholar
• GLICKLICH D, ACHARYA A: Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am. I Kidney Dis. (1998) 32:318–322.
   PubMed Web of Science ®Google Scholar
• BURATTI S, SZER IS, SPENCER H et al: Mycophenolate mofetil (MMF, Cellcept) in the treatment of severe renal disease in pediatric onset systemic lupus erythematosus (SLE). Rheumatol (2001) 289:2103–2108.
   Google Scholar
• GREINER K, VARIKKARA M, SANTIAGO C et al.: Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis. Ophthalmologe (2002) 99(9):691–694.
   PubMedGoogle Scholar
• CANNON GW, PINCUS SH, EMKEY RD et al.: Double-blind trial of recombinant 7-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. (1989) 32:964–973.
   PubMedGoogle Scholar
• PERNICE W, SCHUCHMANN L, DIPPELL J et al.: Therapy for systemic juvenile rheumatoid arthritis with 7-interferon: a pilot study of nine patients. Arthritis Rheum. (1989) 32:643–646.
   PubMedGoogle Scholar
• Immunex Corporation: Enbrel® (etanercept) manufacturer's prescribing information. Immunex Corporation, Seattle, WA, USA (2002).
   Google Scholar
• KUTUKCULER N, CAGLAYAN S, AYDOGDU F: Study of pro-inflammatory (TNF-a, IL-1I3, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin. Rheumatol (1998) 17:288–292.
   PubMed Web of Science ®Google Scholar
• GROM AA, MURRAY KJ, LUYRINK L et al.: Patterns of expression of tumor necrosis factor a, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritic Rheum. (1996) 39:1703–1710.
   PubMed Web of Science ®Google Scholar
• GUERNE PA: Cytokines in juvenile arthritis. Rev Rhum. Engl. Ed (1996) 63:153–158.
   PubMedGoogle Scholar
• LOVELL DJ, GIANNINI EH, REIFF A et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl. Med. (2000) 342:763–769.
   PubMed Web of Science ®Google Scholar
• ••Key paper reporting the first experience ofa biological drug (Enbreln in JA.
   Google Scholar
• GIANNINI EH, RUPERTO N, RAVELLI A et al.: Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. (1997) 40:1202–1209.
   PubMed Web of Science ®Google Scholar
• LOVELL DJ, GIANNINI EH, REIFF A et al.: Long term efficacy and safety of etanercept in children with polyarticular
   Google Scholar
• •• course juvenile rheumatoid arthritis. Arthritis Rheum. (2003) 48:218–226.
   Google Scholar
• REIFF A, TAKEI S, SADEGHI S et al: Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. (2001) 44:1411–1415.
   PubMed Web of Science ®Google Scholar
• REIFF A: Long term outcome of etanercept treatment in children with treatment refractory uveitis (letter). Arthritis Rheum. (2003) 48(7):2079–2080.
   PubMedGoogle Scholar
• •First report about the efficacy of biological drugs (Enbre18) in the treatment of uveitis.
   Google Scholar
• Centocor, Inc.: Remicade® (infliximab) manufacturer's prescribing information. Centocor, Inc., Malvern, PA, USA (1999).
   Google Scholar
• LAHDENNE P, VAHASALO P, HONKANEN V: Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann. Rheum. Dis. (2003) 62(3):245–247.
   PubMed Web of Science ®Google Scholar
• GERLONI V, PONTIKAKI I, DESIATI F et al.: Infliximab in the treatment of persistently active refractory juvenile idiopathic (chronic) arthritis: a short-term pilot study. Arthritis Rheum. (2000) 43(9 Suppl.):S1139.
   Google Scholar
• BILLIAU AD, CORNILLIE F, WOUTERS C: Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children. J. Rheum. (2002) 29(5):1111–1114.
   PubMedGoogle Scholar
• ELLIOTT MJ, WOO P, CHARLES P et al.: Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor- (cA2). Br: J. Rheumatol (1997) 36:589–593.
   Google Scholar
• ROSENBAUM JT, SMITH JR: Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheum. (2002) 20(6 Suppl. 28):143–145.
   Google Scholar
• SFIKAKIS PP, THEODOSSIADIS PG, KATSIARI CG et al.: Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet (2001) 358(9278):295–296.
   PubMed Web of Science ®Google Scholar
• EL-SHABRAWI Y, HERMANN J: Anti-TNF a therapy with infliximab in the treatment of HLA B27 associated acute anterior uveitis- a one year follow up. Arthritis Rheum.(2001) 44 (Suppl. 9):S123.
   Google Scholar
• MOUSER JF, HYAMS JS: Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clin. Titer. (1999) 21:932–942.
   Google Scholar
• VVEINBLATT ME, KEYSTONE EC, FURST DE et al: Adafimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48(1):35–45; Erratum appears in Arthritis Rheum. (2003) 48(3):855.
   Google Scholar
• FURST DH, SCHIFF MH, FLEISCHMANN RM et al.: Adalimumab, a fully human anti-tumor necrosis factor-a monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of star (safety trial of adafimumab in rheumatoid arthritis." Rheum. (2003) 30(12):2563–2571.
   Google Scholar
• RAU R, HERBORN G, SANDER 0 et al.:Long-term treatment with the fully human anti-TNF-antibody D2E7 slows radiographic disease progression in rheumatoid arthritis. Arthritis Rheum. (1999) 42(9 Suppl.):S400.
   Google Scholar
• WOO P, WEDDERBURN LR: Juvenile chronic arthritis. Lancet (1998) 351:969–973.
   PubMed Web of Science ®Google Scholar
• GOTO M, FUJISAWA M, YAMADA A et al.: Spontaneous release of angiotensin converting enzyme and interleukin 113 from peripheral blood monocytes from patients with rheumatoid arthritis under a serum free condition. Ann. Rheum. Dis. (1990) 49:172–176.
   PubMed Web of Science ®Google Scholar
• ZANGERLE PF, DE GROOTE D, LOPEZ M et al.: Direct stimulation of cytokinesTNF-_ IL-6, IL-2, IFN-yand GM-CSF) in whole blood: II. Application to rheumatoid arthritis and osteoarthritis. Cytokine (1992) 4:568-575. loo. BRESNIHAN B, ALVARON-GRACIAJM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. (1998) 41:2196–204.
   Google Scholar
• ILOWITE N, PORRAS 0, REIFF A et al: A twelve-week open label safety and efficacy study of Kinereti (anakinra) in juvenile rheumatoid arthritis. European League Against Rheumatism Meeting, Lisbon, Portugal (2003) (Abstract).
   Google Scholar
• •The first report examining the efficacy of anakinra in children with JA.
   Google Scholar
• DE BENEDETTI F, MASSA M, PIGNATTI P et al.: Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. Clin. Invest. (1994) 93(5):2114–2119.
   Google Scholar
• MAENO N, TAKEI S, NOMURA Y et al: Highly elevated serum levels of interleukin-
   Google Scholar
• in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis or in Kawasaki disease. Arthritis Rheum. 46(9):2539–2541.
   Google Scholar
• ROONEY M, VARSANI H, MARTIN K et al.: Tumour necrosis factor alpha and its soluble receptors in juvenile chronic arthritis. Rheumatology(2000) 39:432–438.
   PubMed Web of Science ®Google Scholar
• KIMURA Y: Etanercept treatment in refractory systemic onset juvenile rheumatoid arthritis. Arthritis Rheum. (2002) 46\(Suppl. 9):51275.
   Google Scholar
• YOKOTA S, MIYAMAE T, IMAGAWA T et al.: Phase II trial of anti IL6 receptor antibody (MRA) for children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. (2003) 48\(Suppl. 9):S1070.
   Google Scholar
• •The first report examining the efficacy of a potential future potent drug, an IL-6-receptor antagonist in children with JA.
   Google Scholar
• WULFFRAAT NM, KUIS W: Autologous stem cell transplantation: a possible treatment for refractory juvenile chronic arthritis? Rheumatology (1999) 38:64–66.
   Web of Science ®Google Scholar
• WULFFRAAT NM, VAN ROYEN A, BIERINGS M et al.: Autologous hemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet (1999) 353:550–553.
   PubMed Web of Science ®Google Scholar
• DUREZ P, FERSTER A, TOUNGOUZ M et al.: Autologous T cell depleted CD34+ peripheral blood stem cell transplantation in four patients with refractory rheumatoid arthritis and juvenile chronic arthritis. Arthritis Rheum. (1999) 42(9 Suppl.):S77. llo. WULFFRAAT NM, BRINKMAN D, FERSTER A et al.: Long term follow up of autologous stem cell transplantation for refractory juvenile idiopathic arthritis. Bonemarrow Transplantation (2003) 32\(Suppl. 1):561–564.
   Google Scholar
• ••The most recent update on the experiencewith bone marrow transplantation in children with JA.
   Google Scholar